The journey of belantamab mafodotin in multiple myeloma
Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD,
Multiple Myeloma
SOHO Insider Podcast
Multiple Myeloma
News
FDA grants accelerated approval to linvoseltamab in relapsed or refractory myeloma
The US Food and Drug Administration has granted accelerated approval to linvoseltamab (Lynozyfic) in adults patients with relapsed or refractory multiple myeloma who
EHA 2025
News
Video Interviews
Low-intensity protocol targets MRD in ALL
In this video interview, Anastasia Vasileva, MD, a researcher at the National Research Center for Hematology in Moscow, discusses findings from a study
2025 ASCO
News
Dr. Kuykendall discusses VERIFY trial, rusfertide’s impact on PV treatment
Andrew Kuykendall, MD, assistant member in Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, discusses the phase 3 VERIFY trial primary results,
Leukemia
Lymphoma
Multiple Myeloma
FDA removes REMS requirement for 6 CAR-T therapies
The US Food and Drug Administration (FDA) has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for all currently approved BCMA- and CD19-directed
Leukemia
Acute Myeloid Leukemia
News
SOHO Insider Podcast
Inside AML challenges with Drs. Jabbour, Daver
Elias Jabbour, MD, and Naval Daver, MD, both of the University of Texas MD Anderson Cancer Center, discuss challenges in TP53-mutated acute myeloid
EHA 2025
Dr. Komrokji reports imetelstat data in high-EPO MDS from EHA 2025
Rami Komrokji, MD, of Moffitt Cancer Center in Tampa, Florida, presented an update at the 2025 European Hematology Association Congress in Milan on
2025 ASCO
Video Interviews
Latest COMMANDS analysis shows luspatercept is transformative in MDS
In this video interview, Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndromes at the University of Texas MD Anderson Cancer Center,
18-IMCL
Lymphoma
Gut-linked microbes tied to survival in DLBCL
The presence of certain intratumoral microbes was linked to survival outcomes in diffuse large B-cell lymphoma (DLBCL), according to findings presented at ICML
18-IMCL
Lymphoma
‘Boom Boom’ Radiotherapy approach may boost CAR T-cell responses
The combination of so-called “Boom Boom” radiotherapy prior to treatment with lisocabtagene maraleucel (liso-cel) was found to be safe, feasible, and effective, according